CompletedPHASE1, PHASE2NCT00975689
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
Studying Niemann-Pick disease type C
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Principal Investigator
- Forbes D Porter, M.D.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Intervention
- N-Acetyl Cysteine(drug)
- Enrollment
- 35 enrolled
- Eligibility
- All sexes
- Timeline
- 2009 – 2010
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Collaborators
University of Oxford · Washington University School of Medicine · National Human Genome Research Institute (NHGRI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00975689 on ClinicalTrials.govOther trials for Niemann-Pick disease type C
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05588167Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type CEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- RECRUITINGPHASE3NCT05163288A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type CIntraBio Inc
- ACTIVE NOT RECRUITINGPHASE3NCT04860960Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1Cyclo Therapeutics, Inc.
- RECRUITINGNANCT00344331Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type CEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)